男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / The Second China International Import Expo

Novo Nordisk introduces new products at CIIE

By Liu Zhihua | chinadaily.com.cn | Updated: 2019-11-08 13:44
Share
Share - WeChat
Denmark's biopharmaceutical company Novo Nordisk has brought a much broader portfolio of healthcare solutions with more Chinese characteristics this year to the CIIE. [Photo provided to chinadaily.com.cn]

Thanks to the continued optimization of the local business environment and the opportunities generated during the deepening of the healthcare reform, Novo Nordisk has made significant progress over the past year in China, and aims to change diabetes for "Healthy China" through showcasing its innovative medicine products at the second China International Import Expo, a senior executive of the Denmark biopharmaceutical company said on Wednesday.

The company's booth at the CIIE 2019 is about 500 square meters, twice of last year. Its INNOVO open innovation platform, digital chronic disease management solution and the "Cities Changing Diabetes" program are all showcased at the CIIE as new attempts over the past few years to expand its industry model and join forces with all parties to address the challenges of diabetes and other metabolic diseases.

Christine Zhou, senior vice-president of the company and president of its China branch, said Novo Nordisk has brought a much broader portfolio of healthcare solutions with more Chinese characteristics this year to CIIE.

China's healthcare reform has been accelerated over the past few years, and Novo Nordisk is not only an observer of the fast development of medical care industry in China but also a beneficiary and a promoter of it, she said.

With the reform of China's new drug review system kicking off in 2015, a slew of the company's new generation basal insulin drugs and injection devices have been approved in China through fast-track path, or are included in the National Reimbursement Drug List, according to her.

Novo Nordisk has also shared its impressive array of achievements from its 25 years' presence in China, including a full range of high-quality therapeutic product portfolio, substantial R&D pipeline, leading-edge global research findings, global digital health care solutions, and the remarkable accomplishments of the Cities Changing Diabetes.

"International exchange and economic and trade cooperation are helping China to develop an open economic development landscape that is very substantial, highly productive and benefiting all the population," Zhou said.

"Through platforms like the CIIE, China is opening up its market to the world while constantly driving the growth of an open global economy – which is an important opportunity for multinational pharmaceutical companies and all other foreign-invested enterprises.

"Novo Nordisk will continue to drive the cause of Changing Diabetes in China and support its Healthy China 2030 vision through innovation and cooperation."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 淮阳县| 卢龙县| 伊金霍洛旗| 福泉市| 田林县| 富民县| 米脂县| 英超| 惠州市| 阜康市| 昔阳县| 滕州市| 凤台县| 津市市| 饶平县| 东兴市| 东丽区| 新津县| 诸暨市| 麦盖提县| 凭祥市| 仁怀市| 郯城县| 宜章县| 浦北县| 宿松县| 肇源县| 巢湖市| 大安市| 敖汉旗| 西贡区| 贵德县| 九龙坡区| 连平县| 南丰县| 望奎县| 西青区| 荆州市| 定陶县| 呼和浩特市| 准格尔旗|